Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Oncologist

Retrieve available abstracts of 62 articles:
HTML format

Single Articles

    December 2021
  1. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    PubMed     Abstract available

  2. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    PubMed     Abstract available

  3. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    PubMed     Abstract available

    November 2021
  4. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    PubMed     Abstract available

    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.

  6. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    PubMed     Abstract available

    October 2021
  7. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    PubMed     Abstract available

  8. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    PubMed     Abstract available

  9. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    PubMed     Abstract available

    September 2021
  10. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    PubMed     Abstract available

  11. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    PubMed     Abstract available

  12. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    PubMed     Abstract available

    August 2021
  13. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    PubMed     Abstract available

  14. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    PubMed     Abstract available

  15. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    PubMed     Abstract available

    July 2021
  16. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    PubMed     Abstract available

  17. LEE Y, Cho Y, Park EY, Park SY, et al
    One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
    Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
    PubMed     Abstract available

  18. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
    PubMed     Abstract available

  19. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
    Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
    PubMed     Abstract available

  20. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed     Abstract available

  21. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    PubMed     Abstract available

    June 2021
  22. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
    Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
    Oncologist. 2021;26:e1085-e1086.

  23. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist. 2021;26:523-532.
    PubMed     Abstract available

    May 2021
  24. ALKREKSHI A, Tamaskar I
    Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Oncologist. 2021;26:e827-e830.
    PubMed     Abstract available

  25. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Oncologist. 2021;26:356-361.
    PubMed     Abstract available

    April 2021
  26. KRUG K, Bossert J, Deis N, Krisam J, et al
    Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
    Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
    PubMed     Abstract available

  27. PERAVALI M, Ahn J, Chen K, Rao S, et al
    Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
    Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
    PubMed     Abstract available

  28. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    PubMed     Abstract available

  29. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.

  30. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    PubMed     Abstract available

  31. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    PubMed     Abstract available

    March 2021
  32. BANDYOPADHYAY A, Sharma S, Behera D, Singh N, et al
    UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Oncologist. 2021 Mar 16. doi: 10.1002/onco.13757.
    PubMed     Abstract available

  33. MATHIEU L, Shah S, Pai-Scherf L, Larkins E, et al
    FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Oncologist. 2021 Mar 9. doi: 10.1002/onco.13752.
    PubMed     Abstract available

  34. RODRIGUEZ-ANTOLIN C, Rosas-Alonso R, Cruz P, Higuera O, et al
    Novel SLC12A2-ROS1 fusion in non-small-cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay.
    Oncologist. 2021 Mar 8. doi: 10.1002/onco.13745.
    PubMed     Abstract available

  35. FRASS M, Lechleitner P, Grundling C, Pirker C, et al
    Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2021;26:e523.

  36. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    PubMed     Abstract available

  37. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    PubMed     Abstract available

    January 2021
  38. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    PubMed     Abstract available

  39. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    PubMed     Abstract available

    November 2020
  40. SCHENK EL, Patil T, Pacheco J, Bunn PA Jr, et al
    2020 Innovation Based Optimism for Lung Cancer Outcomes.
    Oncologist. 2020 Nov 11. doi: 10.1002/onco.13590.
    PubMed     Abstract available

  41. POPAT S, Navani N, Kerr KM, Smit EF, et al
    Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach.
    Oncologist. 2020 Nov 3. doi: 10.1002/onco.13586.
    PubMed     Abstract available

    October 2020
  42. HOLLEN PJ, Gralla RJ, Gentzler RD, Hall RD, et al
    Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.
    Oncologist. 2020 Oct 23. doi: 10.1002/onco.13571.
    PubMed     Abstract available

  43. FRASS M, Lechleitner P, Grundling C, Pirker C, et al
    Homeopathic Treatment as an 'Add on' Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2020 Oct 3. doi: 10.1002/onco.13548.
    PubMed     Abstract available

  44. LE X, Heymach JV
    New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:822-825.
    PubMed     Abstract available

    September 2020
  45. SEHGAL K, Rangachari D, VanderLaan PA, Kobayashi SS, et al
    Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
    Oncologist. 2020 Sep 24. doi: 10.1002/onco.13537.
    PubMed     Abstract available

  46. WONG ML, Gao J, Thanarajasingam G, Sloan JA, et al
    Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729).
    Oncologist. 2020 Sep 20. doi: 10.1002/onco.13527.
    PubMed     Abstract available

  47. HAYASHI H, Niwa T, Yokoyama T, Tanizaki J, et al
    Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020 Sep 12. doi: 10.1002/ONCO.13524.
    PubMed     Abstract available

    August 2020
  48. MELOSKY B, Cheema PK, Brade A, McLeod D, et al
    Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2020 Aug 29. doi: 10.1634/theoncologist.2020-0193.
    PubMed     Abstract available

    July 2020
  49. NOSAKI K, Yamanaka T, Hamada A, Shiraishi Y, et al
    Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
    Oncologist. 2020 Jul 12. doi: 10.1634/theoncologist.2020-0640.
    PubMed     Abstract available

  50. JOHN A, Shah RA, Wong WB, Schneider CE, et al
    Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated With the Use of Companion Diagnostics.
    Oncologist. 2020 Jul 6. doi: 10.1634/theoncologist.2019-0864.
    PubMed     Abstract available

  51. MILBURY K, Li Y, Durrani S, Liao Z, et al
    A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and their Spouses: Results of a 3-Arm Pilot Randomized Controlled Trial.
    Oncologist. 2020 Jul 4. doi: 10.1634/theoncologist.2020-0125.
    PubMed     Abstract available

    June 2020
  52. NAKAMURA A, Tanaka H, Saito R, Suzuki A, et al
    Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
    Oncologist. 2020 Jun 19. doi: 10.1634/theoncologist.2020-0545.
    PubMed     Abstract available

  53. ITCHINS M, Lau B, Hudson AL, Westman H, et al
    ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
    Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0075.
    PubMed     Abstract available

  54. BONANNO L, Pavan A, Ferro A, Calvetti L, et al
    Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
    Oncologist. 2020 Jun 18. doi: 10.1634/theoncologist.2020-0148.
    PubMed     Abstract available

  55. YU Z, Xu Z, He Z, Lai J, et al
    Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Oncologist. 2020 Jun 13. doi: 10.1634/theoncologist.2020-0519.
    PubMed     Abstract available

  56. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
    Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
    Oncologist. 2020 Jun 3. doi: 10.1634/theoncologist.2020-0011.
    PubMed     Abstract available

    May 2020
  57. TAKAYAMA K, Takeshita M, Inoue K, Ichiki M, et al
    Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
    Oncologist. 2020 May 9. doi: 10.1634/theoncologist.2020-0322.
    PubMed     Abstract available

    April 2020
  58. CHOI H, Pennell NA
    Exploring Ways to Improve Access to and Minimize Risk from Lung Cancer Screening.
    Oncologist. 2020 Apr 9. doi: 10.1634/theoncologist.2020-0149.

  59. LIU Y, Hu X, Jiang J, Yang L, et al
    A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
    Oncologist. 2020 Apr 6. doi: 10.1634/theoncologist.2019-0391.
    PubMed     Abstract available

  60. AKAMATSU H, Murakami E, Oyanagi J, Shibaki R, et al
    Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2020;25:e679-e683.
    PubMed     Abstract available

  61. IWAMA E, Goto Y, Murakami H, Tsumura S, et al
    Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
    Oncologist. 2020;25:306-e618.
    PubMed     Abstract available

    March 2020
  62. POPAT V, Lu R, Ahmed M, Park JY, et al
    Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Oncologist. 2020 Mar 31. doi: 10.1634/theoncologist.2019-0814.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.